Overview
Edaravone has demonstrated a beneficial effect in promoting remyelination and protecting axons in animals with NMOSD. The researchers posit that edaravone may enhance visual outcomes in patients with aquaporin-4 antibody-positive optic neuritis.
Eligibility
Inclusion Criteria:
- Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
- Patients with a first episode of optic neuritis in either eye
- First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
Exclusion Criteria:
- Myopia over 6 diopters
- Refractive media opacity affecting assessment of retinal layers and/or visual acuity


